Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial

EJ. Daly, MH. Trivedi, A. Janik, H. Li, Y. Zhang, X. Li, R. Lane, P. Lim, AR. Duca, D. Hough, ME. Thase, J. Zajecka, A. Winokur, I. Divacka, A. Fagiolini, WJ. Cubala, I. Bitter, P. Blier, RC. Shelton, P. Molero, H. Manji, WC. Drevets, JB. Singh

. 2019 ; 76 (9) : 893-903. [pub] 20190901

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21013014

Importance: Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established. Objective: To assess the efficacy of esketamine nasal spray plus an oral antidepressant compared with an oral antidepressant plus placebo nasal spray in delaying relapse of depressive symptoms in patients with TRD in stable remission after an induction and optimization course of esketamine nasal spray plus an oral antidepressant. Design, Setting, and Participants: In this phase 3, multicenter, double-blind, randomized withdrawal study conducted from October 6, 2015, to February 15, 2018, at outpatient referral centers, 705 adults with prospectively confirmed TRD were enrolled; 455 entered the optimization phase and were treated with esketamine nasal spray (56 or 84 mg) plus an oral antidepressant. After 16 weeks of esketamine treatment, 297 who achieved stable remission or stable response entered the randomized withdrawal phase. Interventions: Patients who achieved stable remission and those who achieved stable response (without remission) were randomized 1:1 to continue esketamine nasal spray or discontinue esketamine treatment and switch to placebo nasal spray, with oral antidepressant treatment continued in each group. Main Outcomes and Measures: Time to relapse was examined in patients who achieved stable remission, as assessed using a weighted combination log-rank test. Results: Among the 297 adults (mean age [SD], 46.3 [11.13] years; 197 [66.3%] female) who entered the randomized maintenance phase, 176 achieved stable remission; 24 (26.7%) in the esketamine and antidepressant group and 39 (45.3%) in the antidepressant and placebo group experienced relapse (log-rank P = .003, number needed to treat [NNT], 6). Among the 121 who achieved stable response, 16 (25.8%) in the esketamine and antidepressant group and 34 (57.6%) in the antidepressant and placebo group experienced relapse (log-rank P < .001, NNT, 4). Esketamine and antidepressant treatment decreased the risk of relapse by 51% (hazard ratio [HR], 0.49; 95% CI, 0.29-0.84) among patients who achieved stable remission and 70% (HR, 0.30; 95% CI, 0.16-0.55) among those who achieved stable response compared with antidepressant and placebo treatment. The most common adverse events reported for esketamine-treated patients after randomization were transient dysgeusia, vertigo, dissociation, somnolence, and dizziness (incidence, 20.4%-27.0%), each reported in fewer patients (<7%) treated with an antidepressant and placebo. Conclusions and Relevance: For patients with TRD who experienced remission or response after esketamine treatment, continuation of esketamine nasal spray in addition to oral antidepressant treatment resulted in clinically meaningful superiority in delaying relapse compared with antidepressant plus placebo. Trial Registration: ClinicalTrials.gov identifier: NCT02493868.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21013014
003      
CZ-PrNML
005      
20250402145420.0
007      
ta
008      
210420s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1001/jamapsychiatry.2019.1189 $2 doi
035    __
$a (PubMed)31166571
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Daly, Ella J $u Department of Neuroscience, Janssen Research and Development LLC, Titusville, New Jersey
245    10
$a Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial / $c EJ. Daly, MH. Trivedi, A. Janik, H. Li, Y. Zhang, X. Li, R. Lane, P. Lim, AR. Duca, D. Hough, ME. Thase, J. Zajecka, A. Winokur, I. Divacka, A. Fagiolini, WJ. Cubala, I. Bitter, P. Blier, RC. Shelton, P. Molero, H. Manji, WC. Drevets, JB. Singh
520    9_
$a Importance: Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established. Objective: To assess the efficacy of esketamine nasal spray plus an oral antidepressant compared with an oral antidepressant plus placebo nasal spray in delaying relapse of depressive symptoms in patients with TRD in stable remission after an induction and optimization course of esketamine nasal spray plus an oral antidepressant. Design, Setting, and Participants: In this phase 3, multicenter, double-blind, randomized withdrawal study conducted from October 6, 2015, to February 15, 2018, at outpatient referral centers, 705 adults with prospectively confirmed TRD were enrolled; 455 entered the optimization phase and were treated with esketamine nasal spray (56 or 84 mg) plus an oral antidepressant. After 16 weeks of esketamine treatment, 297 who achieved stable remission or stable response entered the randomized withdrawal phase. Interventions: Patients who achieved stable remission and those who achieved stable response (without remission) were randomized 1:1 to continue esketamine nasal spray or discontinue esketamine treatment and switch to placebo nasal spray, with oral antidepressant treatment continued in each group. Main Outcomes and Measures: Time to relapse was examined in patients who achieved stable remission, as assessed using a weighted combination log-rank test. Results: Among the 297 adults (mean age [SD], 46.3 [11.13] years; 197 [66.3%] female) who entered the randomized maintenance phase, 176 achieved stable remission; 24 (26.7%) in the esketamine and antidepressant group and 39 (45.3%) in the antidepressant and placebo group experienced relapse (log-rank P = .003, number needed to treat [NNT], 6). Among the 121 who achieved stable response, 16 (25.8%) in the esketamine and antidepressant group and 34 (57.6%) in the antidepressant and placebo group experienced relapse (log-rank P < .001, NNT, 4). Esketamine and antidepressant treatment decreased the risk of relapse by 51% (hazard ratio [HR], 0.49; 95% CI, 0.29-0.84) among patients who achieved stable remission and 70% (HR, 0.30; 95% CI, 0.16-0.55) among those who achieved stable response compared with antidepressant and placebo treatment. The most common adverse events reported for esketamine-treated patients after randomization were transient dysgeusia, vertigo, dissociation, somnolence, and dizziness (incidence, 20.4%-27.0%), each reported in fewer patients (<7%) treated with an antidepressant and placebo. Conclusions and Relevance: For patients with TRD who experienced remission or response after esketamine treatment, continuation of esketamine nasal spray in addition to oral antidepressant treatment resulted in clinically meaningful superiority in delaying relapse compared with antidepressant plus placebo. Trial Registration: ClinicalTrials.gov identifier: NCT02493868.
650    _2
$a aplikace intranazální $7 D000281
650    _2
$a aplikace orální $7 D000284
650    _2
$a dospělí $7 D000328
650    _2
$a antidepresiva $x aplikace a dávkování $x škodlivé účinky $x farmakologie $7 D000928
650    _2
$a depresivní porucha unipolární $x farmakoterapie $7 D003865
650    _2
$a deprese nereagující na léčbu $x farmakoterapie $7 D061218
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a ketamin $x aplikace a dávkování $x škodlivé účinky $x farmakologie $7 D007649
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nosní spreje $7 D059085
650    12
$a hodnocení výsledků zdravotní péče $7 D017063
650    _2
$a indukce remise $7 D012074
650    12
$a sekundární prevence $7 D055502
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Trivedi, Madhukar H $u Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas
700    1_
$a Janik, Adam $u Department of Neuroscience, Janssen Research and Development LLC, San Diego, California
700    1_
$a Li, Honglan $u Department of Neuroscience, Janssen Research and Development LLC, Titusville, New Jersey
700    1_
$a Zhang, Yun $u Department of Clinical Biostatistics, Janssen Research and Development LLC, Fremont, California
700    1_
$a Li, Xiang $u Department of Clinical Biostatistics, Janssen Research and Development LLC, Raritan, New Jersey
700    1_
$a Lane, Rosanne $u Department of Clinical Biostatistics, Janssen Research and Development LLC, Titusville, New Jersey
700    1_
$a Lim, Pilar $u Department of Clinical Biostatistics, Janssen Research and Development LLC, Titusville, New Jersey
700    1_
$a Duca, Anna R $u Department of Neuroscience, Janssen Research and Development LLC, Titusville, New Jersey
700    1_
$a Hough, David $u Department of Neuroscience, Janssen Research and Development LLC, Titusville, New Jersey
700    1_
$a Thase, Michael E $u Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia
700    1_
$a Zajecka, John $u Department of Psychiatry, Rush University Medical Center, Chicago, Illinois
700    1_
$a Winokur, Andrew $u Department of Psychiatry, University of Connecticut Health, Farmington $u Institute of Living, Hartford, Connecticut
700    1_
$a Divacka, Ilona $u Private practice, Prague, Czech Republic
700    1_
$a Fagiolini, Andrea $u Department of Molecular Medicine, Division of Psychiatry, University of Siena, Siena, Italy
700    1_
$a Cubala, Wieslaw J $u Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
700    1_
$a Bitter, István, $d 1949- $u Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary $7 xx0330815
700    1_
$a Blier, Pierre $u Departments of Psychiatry and Cellular/Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
700    1_
$a Shelton, Richard C $u Department of Psychiatry, University of Alabama School of Medicine, Birmingham
700    1_
$a Molero, Patricio $u Department of Psychiatry, Clinica Universidad de Navarra, Pamplona, Spain
700    1_
$a Manji, Husseini $u Department of Neuroscience, Janssen Research and Development LLC, Titusville, New Jersey
700    1_
$a Drevets, Wayne C $u Department of Neuroscience, Janssen Research and Development LLC, San Diego, California
700    1_
$a Singh, Jaskaran B $u Department of Neuroscience, Janssen Research and Development LLC, San Diego, California
773    0_
$w MED00180928 $t JAMA psychiatry $x 2168-6238 $g Roč. 76, č. 9 (2019), s. 893-903
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31166571 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20250402145416 $b ABA008
999    __
$a ok $b bmc $g 1651243 $s 1133393
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 76 $c 9 $d 893-903 $e 20190901 $i 2168-6238 $m JAMA psychiatry $n JAMA Psychiatry $x MED00180928
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace